ANALIZE MEDICALE DE LABORATOR
Aici gasiti analizele medicale grupate pe categorii precum si detalii generale si specifice pentru categoriile respective.
Selectati o categorie din lista de mai jos:
Solutie antistress!
Construieste poduri :)
Prinde pisica neagra :)
Idenix Pharmaceuticals Provides Update On Hepatitis C Pipeline At JP Morgan Healthcare Conference
Idenix Pharmaceuticals,
Inc. (Nasdaq: IDIX), a biopharmaceutical company engaged in the discovery
and development of drugs for the treatment of human viral and other
infectious diseases, today announced an update on the company's HCV
pipeline, including promising second-generation polymerase and protease
inhibitor compounds for the treatment of hepatitis C. This update will be
presented on Tuesday, January 8, at 2:30 p.m. PT at the JP Morgan
Healthcare Conference in San Francisco, CA.
Second-Generation Nucleoside Polymerase Inhibitor Program
Idenix's preclinical HCV nucleoside polymerase inhibitor program
comprises two novel nucleotide prodrugs, IDX184 and IDX102. This program is
based on Idenix's proprietary liver-targeting technology, which delivers
high levels of nucleoside triphosphate in the liver, potentially maximizing
drug efficacy and limiting systemic side effects.
In preclinical studies using an HCV replicon assay, IDX184 exhibited 10
times greater potency than nucleosides currently in clinical development.
In a 7-day preclinical toxicology study of IDX184, no toxicities, including
gastrointestinal or hematological, were observed in monkeys at doses
greater than or equal to 600 mg/kg/day. In HCV genotype-1 infected
chimpanzees, once- daily oral administration of 10 mg/kg of either
nucleotide prodrug produced a rapid and potent inhibition of HCV
replication with mean viral load reductions ranging from 1.5 log(10) with
IDX102 to 2.5-4.0 log(10) with IDX184 after 4 days of dosing. IDX184 has
been selected as the company's lead candidate from this program and
clinical data are expected in 2008.
Novel Macrocyclic Protease Inhibitor Program
Idenix is evaluating multiple scaffolds in its protease inhibitor
discovery program. Compounds from two of these scaffolds have demonstrated
potent and selective antiviral activity in in vitro preclinical studies to
date. Several compounds have demonstrated subnanomolar potency against the
HCV NS3 protease target, single nanomolar potency in the HCV replicon, and
no inhibition of 8 human cellular proteases. Initial preclinical
pharmacokinetic evaluation of these compounds suggests the potential for
once-daily or twice- daily dosing. Clinical candidates from this program
have been selected and IND-enabling toxicology studies are ongoing.
"Our second-generation HCV drug candidates could offer improvements
over direct-acting compounds currently in clinical development," said
Jean-Pierre Sommadossi, Idenix's chairman and chief executive officer. "For
example, in preclinical studies our second-generation polymerase inhibitor,
IDX184, delivered multi-log viral load reductions in HCV genotype-1
infected chimpanzees in just 4 days -- on par with the antiviral activity
reported to date from protease inhibitors currently in development."
Sommadossi continued, "In 2008, we look forward to advancing our
nucleotide prodrug and macrocyclic protease inhibitor programs into the
clinic to determine whether the promising preclinical data generated to
date bears out in HCV-infected patients. If successful, the combination of
our second- generation polymerase and protease inhibitors could lead to
very exciting changes in the HCV treatment paradigm."
About Idenix
Idenix Pharmaceuticals, Inc., headquartered in Cambridge,
Massachusetts, is a biopharmaceutical company engaged in the discovery and
development of drugs for the treatment of human viral and other infectious
diseases. Idenix's current focus is on the treatment of infections caused
by hepatitis C virus and HIV. For further information about Idenix, please
refer to http://www.idenix.com.
Forward-looking Statements
This press release contains "forward-looking statements" within the
meaning of The Private Securities Litigation Reform Act of 1995. Such
forward- looking statements can be identified by the use of forward-looking
terminology such as "could," "may," "plans," "will," or similar
expressions, or by express or implied statements with respect to the
company's clinical development programs in hepatitis C, or any potential
pipeline candidates for the treatment of hepatitis C. Such forward-looking
statements involve known and unknown risks, uncertainties and other factors
that may cause actual results to be materially different from any future
results, performance or achievements expressed or implied by such
statements. There can be no guarantees that the company will advance any
clinical product candidate or other component of its potential pipeline to
the clinic, to the regulatory process or to commercialization. In
particular, management's expectations could be affected by unexpected
regulatory actions or delays; uncertainties relating to, or unsuccessful
results of, pre-clinical studies and/or clinical trials, including
additional data relating to the ongoing pre-clinical studies and/or
clinical trials evaluating its product candidates; the company's ability to
obtain additional funding required to conduct its research, development and
commercialization activities; the company's dependence on its collaboration
with Novartis Pharma AG; changes in the company's business plan or
objectives; the ability of the company to attract and retain qualified
personnel; competition in general; and the company's ability to obtain,
maintain and enforce patent and other intellectual property protection for
its product candidates and its discoveries. These and other risks which may
impact management's expectations are described in greater detail under the
caption "Risk Factors" in the company's annual report on Form 10-K for the
year ended December 31, 2006 and the Quarterly Report on Form 10-Q for the
quarter ended September 30, 2007, each as filed with the Securities and
Exchange Commission (SEC) and other filings that the company makes with the
SEC.
All forward-looking statements reflect the company's expectations only
as of the date of this release and should not be relied upon as reflecting
the company's views, expectations or beliefs at any date subsequent to the
date of this release. Idenix anticipates that subsequent events and
developments may cause these views, expectations and beliefs to change.
However, while Idenix may elect to update these forward-looking statements
at some point in the future, it specifically disclaims any obligation to do
so.
Idenix Pharmaceuticals, Inc.
http://www.idenix.com
Idenix Pharmaceuticals Oferã Update Pe Hepatita C conducte La JP Morgan Healthcare Conferinta - Idenix Pharmaceuticals Provides Update On Hepatitis C Pipeline At JP Morgan Healthcare Conference - articole medicale engleza - startsanatate